All News

2019

January

Media Release / Jan 07, 2019

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

Read More
2018

December

Media Release / Dec 19, 2018

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

Read More
Media Release / Dec 18, 2018

Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Read More
Media Release / Dec 10, 2018

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

Read More
Media Release / Dec 04, 2018

Sandoz certified Top Employer Asia Pacific 2019

Read More

November

Media Release / Nov 27, 2018

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

Read More
Media Release / Nov 20, 2018

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

Read More
Media Release / Nov 07, 2018

Sandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR)

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More